SAN DIEGO--(BUSINESS WIRE)--AlivaMab Discovery Services, LLC, ("ADS") a leader in comprehensive, integrated solutions for antibody drug discovery, announced the planned transition of its chief executive officer from Larry Green, PhD, to Justin Mika, effective May 6, 2020. Dr. Green will become chairman of the board of directors of ADS. Dr. Green remains as CEO of Ablexis, LLC and will continue to work closely with the team at ADS to advance the companies' combined goal of delivering antibody drug candidates of the highest quality.
As CEO, Mr. Mika will lead the continued growth of ADS' business as the best-in-class provider of antibody drug discovery platform services. He joins ADS from Eurofins DiscoverX, where he was senior vice president of the drug discovery division at Eurofins and General Manager of Eurofins DiscoverX. Joining DiscoverX in 2006, he helped grow the company through roles of increasing responsibility, finally serving as Senior Vice President and General Manager in its acquisition by Eurofins in 2017. He has a B.Sc., Biology and Molecular Biology Concentration from Pennsylvania State University and a M.Sc. in Organizational Development and Change Management and a Masters of Business Administration degree from the University of Delaware.
“Justin's track record of success evidences that he is the perfect fit to lead AlivaMab Discovery Services in its next phases of growth,” said Dr. Green. “He understands our market, is an experienced leader and possesses a customer-first mindset. Under his leadership, ADS will advance performance and operational improvements and innovations to deliver even better client satisfaction.”
“I am extremely proud of the accomplishments of the ADS team in building the business and repeatedly demonstrating the ability to produce and identify, in only a few weeks, diverse panels of candidate-quality human antibodies for both straightforward and challenging projects for our clients,” Dr. Green continued. “I am also proud that in only one year of client services, ADS is exceeding its business metrics, including repeat customers, new customers and revenue growth. Personally, this is a bittersweet decision for me, saddening to leave the day-to-day workings with the ADS family and happy to return to San Francisco for more time with my partner and dogs.”
“I look forward to working with the talented team at ADS and am pleased that the board of directors has entrusted me to lead its ongoing innovation and expansion,” said Mr. Mika. “The integrated, comprehensive offerings of ADS combined with Ablexis' AlivaMab® Mouse platform hit the sweet spot between competitors' offerings. The clients of ADS, which range from global pharmaceutical companies to companies operating virtually, understand that the success of a project, both in the short-term and long-term, is founded on what ADS does best: efficiently and cost-effectively generating, characterizing and delivering fully human antibodies that meet target product profiles in industry-leading timelines.”
About AlivaMab Discovery Services (ADS)
AlivaMab Discovery Services is dedicated to our partners' successes in the discovery and development of human therapeutic antibodies. ADS’ fully-integrated therapeutic antibody discovery platform leverages the team’s expertise built on cumulative decades of experience in building and using antibody drug discovery platforms and processes, which includes the execution of over 200 discovery projects that has yielded several dozen antibody drug candidates in clinical trials, and seven approved antibody drugs. Our drug discovery experience crosses diverse therapeutic areas including oncology, autoimmune and inflammatory disease, metabolic, ocular, and infectious disease.
AlivaMab Discovery Services uses the AlivaMab Mouse of Ablexis, LLC to deliver panels of high affinity therapeutic antibody candidates, with extensive molecular and epitope diversities, functional and kinetic characterization, with unmatched speed. With the broad and deep expertise of the ADS team, we develop innovative solutions for immunizations, antibody recovery, antibody screening, and functional assay development and execution for even the most difficult project to give clients of ADS a distinct advantage for their antibody drug discovery projects.